BCDA revenueQ4 2025$0
- FY YoY
- -100.0%
BCDA revenue was $0 in fiscal Q4 2025 (ended Dec 31, 2025), compared with $0 a year earlier. For the full fiscal 2025 it was $0, down 100.0% from fiscal 2024.
BioCardia Inc. (BCDA) financials
For fiscal 2025 (ended Dec 31, 2025), BioCardia Inc. reported $0 of revenue and -$8.23M of net income.
- Revenue, FY2025
- $0
- Revenue growth, YoY
- -100.0%
- Net income, FY2025
- -$8.23M
- Free cash flow, FY2025
- -$7.44M
- Cash
- $4.12M
- Market cap
- $13.6M
FY2016FY2025
FY2016FY2025
FY2017FY2025
BCDA revenue and earnings growth
BCDA net incomeQ2 2026-$1.61M
BCDA net income was -$1.61M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.05M a year earlier. For the full fiscal 2025 it was -$8.23M, compared with -$7.95M in fiscal 2024.
BCDA EPSQ1 2026-$0.21
BCDA diluted EPS was -$0.21 in fiscal Q1 2026 (ended Mar 31, 2026). For the full fiscal 2021 it was -$0.75.
BCDA free cash flowQ2 2026-$1.74M
BCDA free cash flow was -$1.74M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.65M a year earlier. For the full fiscal 2025 it was -$7.44M, compared with -$7.89M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $58.0K | $477.0K | $1.35M | $1.01M | $145.0K | $710.0K | $625.0K | $479.0K | $576.0K |
| Cost of revenue | - | - | - | - | $0 | $4.0K | $358.0K | $517.0K | $690.0K | $746.0K |
| Gross profit | - | - | - | - | $1.01M | $141.0K | $352.0K | $108.0K | -$211.0K | -$170.0K |
| Research and development | $4.96M | $4.39M | $7.73M | $8.83M | $8.56M | $9.81M | $8.56M | $8.45M | $5.80M | $3.33M |
| Selling, general and admin | $3.32M | $3.67M | $4.39M | $4.42M | $5.09M | $5.86M | $6.00M | $5.76M | $6.39M | $4.11M |
| Operating income | -$8.28M | -$8.00M | -$11.64M | -$11.90M | -$12.63M | -$15.53M | -$14.21M | -$14.10M | -$12.40M | -$7.61M |
| Interest expense | - | - | - | - | $0 | $3.0K | $112.0K | - | $0 | $1.74M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.23M | -$7.95M | -$11.57M | -$11.91M | -$12.62M | -$15.00M | -$14.71M | -$13.99M | -$12.31M | -$10.31M |
| EPS, basic | -$1.23 | -$2.90 | -$8.19 | -$0.67 | -$0.75 | -$1.48 | -$2.61 | -$3.28 | -$2.90 | -$11.07 |
| EPS, diluted | - | - | - | - | -$0.75 | -$1.48 | -$2.61 | -$3.28 | -$2.90 | -$11.07 |
| Diluted shares | - | - | - | - | 16.9M | 10.1M | 5.6M | 4.3M | 4.2M | 929,809.333 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.50M | $2.37M | $1.10M | $7.36M | $12.87M | $21.41M | $5.58M | $5.36M | $12.69M | $21.35M |
| Receivables | $20.0K | $0 | $63.0K | $201.0K | $147.0K | $232.0K | $147.0K | $274.0K | $95.0K | $74.0K |
| Inventory | - | - | - | - | - | - | $4.0K | $141.0K | $191.0K | $135.0K |
| Current assets | $2.73M | $2.62M | $1.46M | $7.86M | $13.48M | $22.66M | $6.38M | $6.22M | $13.31M | $21.92M |
| Total assets | $3.41M | $3.72M | $2.99M | $9.79M | $15.72M | $23.42M | $7.68M | $6.42M | $13.54M | $22.08M |
| Current liabilities | $2.43M | $2.32M | $3.61M | $3.58M | $3.71M | $4.25M | $4.00M | $2.55M | $2.33M | $1.44M |
| Total liabilities | $2.52M | $2.89M | $4.59M | $4.90M | $5.34M | $4.25M | $5.31M | $2.63M | $2.41M | $1.50M |
| Shareholders' equity | $895.0K | $837.0K | -$1.60M | $4.89M | $10.38M | $19.18M | $2.37M | $3.79M | $11.13M | $20.58M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.44M | -$7.89M | -$9.97M | -$10.56M | -$10.37M | -$12.36M | -$9.45M | -$11.07M | -$8.67M | -$5.52M |
| Capital expenditures | $7.0K | $6.0K | $12.0K | $70.0K | $116.0K | $32.0K | $146.0K | $66.0K | $136.0K | - |
| Free cash flow | -$7.44M | -$7.89M | -$9.99M | -$10.63M | -$10.48M | -$12.39M | -$9.59M | -$11.13M | -$8.81M | - |
| Investing cash flow | -$7.0K | -$6.0K | -$12.0K | -$70.0K | -$116.0K | -$32.0K | -$146.0K | -$66.0K | -$136.0K | $18.92M |
| Financing cash flow | $7.57M | $9.16M | $3.73M | $5.12M | $1.95M | $28.21M | $9.82M | $3.80M | $144.0K | $4.40M |
| Stock-based compensation | $430.0K | $741.0K | $1.03M | $1.18M | $1.66M | $2.95M | $2.72M | $2.77M | $2.71M | $942.0K |
| Depreciation and amortization | $24.0K | $67.0K | $84.0K | $82.0K | $60.0K | $68.0K | $111.0K | $88.0K | $78.0K | $39.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | -87.8% | -64.7% | 33.2% | 600.0% | -79.6% | 13.6% | 30.5% | -16.8% | -36.3% |
| Gross margin | - | - | - | - | 100.0% | 97.2% | 49.6% | 17.3% | -44.1% | -29.5% |
| Operating margin | - | -13794.8% | -2441.1% | -880.3% | -1244.3% | -10709.7% | -2001.8% | -2256.3% | -2589.8% | -1320.8% |
| Net margin | - | -13700.0% | -2425.8% | -880.7% | -1243.6% | -10347.6% | -2071.7% | -2237.9% | -2569.5% | -1789.9% |
| Free cash flow margin | - | -13606.9% | -2093.5% | -786.3% | -1032.7% | -8544.1% | -1350.8% | -1781.6% | -1838.6% | - |
| Return on equity | -919.3% | -949.3% | - | -243.4% | -121.7% | -78.2% | -620.6% | -368.9% | -110.6% | -50.1% |
| Return on assets | -241.1% | -213.4% | -387.4% | -121.6% | -80.3% | -64.1% | -191.6% | -218.0% | -90.9% | -46.7% |
| Current ratio | 1.12 | 1.13 | 0.40 | 2.19 | 3.63 | 5.33 | 1.59 | 2.44 | 5.71 | 15.18 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $3.0K | $55.0K | $13.0K | $357.0K |
| Research and development | $893.0K | $1.24M | $1.13M | $936.0K | $1.37M | $1.53M | $1.42M | $931.0K | $800.0K | $1.24M | $1.16M | $1.87M |
| Selling, general and admin | $730.0K | $1.03M | $885.0K | $552.0K | $683.0K | $1.20M | $906.0K | $825.0K | $852.0K | $1.09M | $941.0K | $1.08M |
| Operating income | -$1.62M | -$2.27M | -$2.01M | -$1.49M | -$2.05M | -$2.73M | -$2.32M | -$1.76M | -$1.65M | -$2.27M | -$2.08M | -$2.60M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$1.61M | -$2.26M | -$1.98M | -$1.48M | -$2.05M | -$2.71M | -$2.30M | -$1.74M | -$1.65M | -$2.27M | -$2.07M | -$2.57M |
| EPS, basic | -$0.13 | -$0.21 | - | -$0.24 | -$0.40 | -$0.59 | - | -$0.61 | -$0.88 | -$1.35 | - | -$1.79 |
| EPS, diluted | - | -$0.21 | - | - | -$0.40 | -$0.59 | - | - | - | - | - | - |
| Diluted shares | - | 10.8M | - | - | 5.1M | 4.6M | - | - | - | - | - | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.12M | $951.0K | $2.50M | $5.29M | $980.0K | $949.0K | $2.37M | $4.93M | $1.42M | $949.0K | $1.10M | $1.83M |
| Receivables | $30.0K | $20.0K | $20.0K | - | $10.0K | - | $0 | $10.0K | $10.0K | $58.0K | $63.0K | $104.0K |
| Current assets | $4.30M | $1.14M | $2.73M | $5.37M | $1.20M | $1.17M | $2.62M | $5.06M | $1.57M | $1.26M | $1.46M | $2.12M |
| Total assets | $4.75M | $1.71M | $3.41M | $6.15M | $2.09M | $2.17M | $3.72M | $6.27M | $2.89M | $2.68M | $2.99M | $3.75M |
| Current liabilities | $2.06M | $2.78M | $2.43M | $3.31M | $3.64M | $3.23M | $2.32M | $2.84M | $4.07M | $4.07M | $3.61M | $3.33M |
| Total liabilities | $2.06M | $2.78M | $2.52M | $3.52M | $3.98M | $3.69M | $2.89M | $3.51M | $4.85M | $4.95M | $4.59M | $4.41M |
| Shareholders' equity | $2.70M | -$1.07M | $895.0K | $2.63M | -$1.89M | -$1.52M | $837.0K | $2.75M | -$1.96M | -$2.27M | -$1.60M | -$660.0K |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.74M | -$1.66M | -$2.50M | -$1.67M | -$1.65M | -$1.62M | -$2.43M | -$2.61M | -$1.31M | -$1.53M | -$1.85M | -$2.41M |
| Capital expenditures | $0 | $3.0K | $6.0K | $0 | $1.0K | $0 | $1.0K | $2.0K | $3.0K | $0 | $0 | $0 |
| Free cash flow | -$1.74M | -$1.66M | -$2.50M | -$1.67M | -$1.65M | -$1.62M | -$2.43M | -$2.61M | -$1.31M | -$1.53M | -$1.85M | -$2.41M |
| Investing cash flow | $0 | -$3.0K | -$6.0K | $0 | -$1.0K | $0 | -$1.0K | -$2.0K | -$3.0K | $0 | $0 | $0 |
| Financing cash flow | $4.90M | $117.0K | -$288.0K | $5.98M | $1.68M | $196.0K | -$125.0K | $6.12M | $1.79M | $1.38M | $1.12M | -$58.0K |
| Stock-based compensation | $109.0K | $113.0K | $85.0K | $77.0K | $98.0K | $170.0K | $176.0K | $177.0K | $184.0K | $204.0K | $184.0K | $251.0K |
| Depreciation and amortization | $3.0K | $3.0K | $3.0K | $4.0K | $5.0K | $12.0K | $15.0K | $16.0K | $17.0K | $19.0K | $20.0K | $21.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | -100.0% | -100.0% | -100.0% | -100.0% | -93.0% | -14.1% | -87.7% | 68.4% |
| Operating margin | - | - | - | - | - | - | - | - | -54966.7% | -4136.4% | -16030.8% | -727.7% |
| Net margin | - | - | - | - | - | - | - | - | -54866.7% | -4121.8% | -15938.5% | -721.0% |
| Free cash flow margin | - | - | - | - | - | - | - | - | -43833.3% | -2781.8% | -14238.5% | -675.6% |
| Current ratio | 2.09 | 0.41 | 1.12 | 1.62 | 0.33 | 0.36 | 1.13 | 1.78 | 0.39 | 0.31 | 0.40 | 0.64 |
Source: XBRL data BioCardia Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-12, first reported Mar 16, 2018; 1-for-9, first reported Aug 14, 2019.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
BCDA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BCDA | $0 | -100.0% | -$8.23M | - | $13.6M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
BCDA FAQ
7 questionsWhat is BCDA revenue?
BioCardia Inc. (BCDA) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is BCDA profitable?
No. BioCardia Inc. reported a net loss of $8.23M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does BCDA have?
BioCardia Inc. reported $4.12M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is BCDA revenue growing?
BioCardia Inc.'s revenue changed -100.0% in fiscal 2025, to $0.What is BCDA free cash flow?
BioCardia Inc. generated -$7.44M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$7.44M less capital expenditures.When did BCDA last report financial results?
The latest statements here come from BioCardia Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this BCDA financial data come from?
Quantisnow builds these statements from the structured XBRL data BioCardia Inc. files with the SEC. It is provided for information only and is not investment advice.